Most Recent Articles by Diana Ernst, RPh
Researchers conducted a retrospective matched cohort study to compare the risk of death among BPH patients treated with 5ARIs, as monotherapy or in combination with alpha-blockers, and those treated with alpha-blockers alone.
The Food and Drug Administration (FDA) has approved Heplisav-B for the prevention of infection caused by all known subtypes of hepatitis B virus.
The Advisory Committee on Immunization Practices has released the guidelines for the 2017-2018 season.
The FDA Drug Interactions section has been updated to include revised information on concomitant use of corticosteroids with these drugs.
Among GERD patients, the mean annual ARI episode dropped from 4.39 during the year before PPI treatment to 3.89 after treatment with a PPI.